The Prosigna 50-gene profile and responsiveness to adjuvant anthracycline-based chemotherapy in high-risk breast cancer patients

The DBCG89D trial randomized high-risk early breast cancer patients to adjuvant CMF (cyclophosphamide, methotrexate and fluorouracil) or CEF (cyclophosphamide, epirubicin and fluorouracil). Prosigna assays were performed by researchers with no access to clinical data. Time to distant recurrence (DR)...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:NPJ Breast Cancer
Huvudupphovsmän: Jensen, Maj-Britt, Lænkholm, Anne-Vibeke, Balslev, Eva, Buckingham, Wesley, Ferree, Sean, Glavicic, Vesna, Dupont Jensen, Jeanette, Søegaard Knoop, Ann, Mouridsen, Henning T., Nielsen, Dorte, Nielsen, Torsten O., Ejlertsen, Bent
Materialtyp: Artigo
Språk:Inglês
Publicerad: Nature Publishing Group UK 2020
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7044229/
https://ncbi.nlm.nih.gov/pubmed/32140564
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41523-020-0148-0
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk